Zoledronic Acid (Zometa®)

Common name: Zoledronic Acid
Brand name: Zometa®
 

What is Zoledronic Acid?

Zoledronic Acid belongs to the class of drugs known as bisphosphonates that are used to treat bone metastases that result from prostate cancer. Zoledronic Acid prevents or slows the rate of bone change (including the breakdown of the bone).


How is Zoledronic Acid administered?

Zoledronic Acid is administered by intravenous injection.


What are possible side effects of this treatment?

Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received zoledronic acid. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Bone / joint pain
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Loss of appetite
  • Nausea / vomiting
  • Weight loss


Is Zoledronic Acid covered in my province or territory?

Zoledronic acid is covered by provincial drug programs in:
  • Alberta (special authorization)
  • British Columbia (palliative)
  • Manitoba
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
  • Northwest Territories
  • Yukon (covered by individual hospitals)
Zoledronic acid is not covered by provincial drug programs in:
  • Prince Edward Island
Unknown if zoledronic acid is covered by provincial drug programs in:
  • ​Nunavut

Zometa Patient Assistance Program (Access Zometa)

Patient Assistance Programs are offered by pharmaceutical companies to provide medications to those who cannot afford to pay for their medicine.

Please call 1-866-281-4765 weekdays between 8am and 6pm EST for more information and to see if you qualify for this program.


 

Last Reviewed: July 2017




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.
More

Can exercise help slow prostate cancer growth?

Toronto, March 12, 2018 – Funded by Prostate Cancer Canada (PCC), Dr.
More

Prostate Cancer Canada’s Rock the Road Raffle sells out for 5th consecutive year

February 23, 2018 – TORONTO, ON – For the fifth year and counting, Prostate Cancer Canada’s (PCC) Rock the Road Raffle brought together Ontarians from all walks of life to both support an important cause and gain a chance to win a one-of-a-kind dream car.
More


Click here for news archive